Análisis de costo-efectividad de dabigatran, rivaroxaban y apixaban comparado con warfarina para prevención de fenómenos tromboembólicos e isquémicos en pacientes adultos con fibrilación auricular no valvular en Colombia

Arce Correa, Juan Felipe; Ceballos, Mateo; Peña, Esperanza; Mejía Mejía, Aurelio; García, Ángel; Payares Álvarez, Kelly.
Bogotá; IETS; mayo 2016. 69 p. tab, ilus.
Monografia em Espanhol | BRISA, LILACS | ID: biblio-837465

Documentos relacionados

  1. Fund Black scientists.
  2. [Comparison of the cost-utility of direct oral anticoagulants for the prevention of stroke in patients with atrial fibrillation in Spain].
  3. A cost comparison of warfarin vs enoxaparine or new oral anticoagulants used for the treatment of patients with pulmonary embolism.
  4. Development and Impact of an Institutional Enhanced Recovery Program on Opioid Use, Length of Stay, and Hospital Costs Within an Academic Medical Center: A Cohort Analysis of 7774 Patients.
  5. A Direct Oral Anticoagulant as a Cost Effective Alternative to Warfarin for Treatment of Provoked Venous Thrombosis.
  6. [The cost of pulmonary thromboembolism treatment].
  7. Global access to affordable direct oral anticoagulants.
  8. Attitude changes in prescribing intravenous iron supplementation in different settings at a hospital consortium in Italy.
  9. Principal-agent theory-based cost and reimbursement structures of isavuconazole treatment in German hospitals.
  10. From scientific discovery to cures: bright stars within a galaxy.